Gain Therapeutics, Inc. (GANX)
NASDAQ:GANX
Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$2.13
-$0.01(-0.44%)
At close: 4:00 PM EST
$2.13
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)625.35K
Market Cap
$76.35M
Enterprise Value$66.93M
Total Cash (Recent Filing)$16.54M
Total Debt (Recent Filing)$298.76K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding42,654,037
10 Day Avg. Volume853,146
30 Day Avg. Volume625,353
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.42
Forecast
1Y Price Target
$7.20Price Target Upside238.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data: GT-02287 Safety & RetentionRobust safety/tolerability and very high participant retention in the Phase 1b extension reduce clinical development risk and preserve trial continuity. Durable safety and adherence improve chances of moving into later trials and attract partners or financers over the medium term.
Biomarker-driven Efficacy SignalsClear biomarker reductions (GluSph) coupled with a measured motor-score advantage in a defined subgroup support target engagement and a precision-development strategy. Such mechanism-linked signals can materially raise the probability of phase‑2/3 success and enable focused regulatory and commercial planning.
Very Low Financial LeverageMinimal debt reduces short-term insolvency risk and preserves strategic flexibility for R&D and partnering. Low leverage makes equity financing or collaborations less encumbered by covenant constraints, supporting sustained investment in clinical programs over the coming months.
Bears Say
Persistent Negative Cash FlowSignificant, ongoing operating and free cash outflows indicate the company is burning cash at scale. This steady burn creates a continuous need for external funding, raising dilution and execution risk if financing markets tighten or development timelines extend beyond current runway.
Pre-revenue With Large LossesBeing pre-revenue with substantial net losses means no internal product cash flows to offset R&D spend. Continued negative profitability through early clinical stages lengthens time to self-sustaining margins and increases reliance on capital markets or partners to fund pivotal trials.
Declining Equity BaseA falling equity base signals capital erosion and/or dilution tied to recurring losses and financing activity. This trend heightens financing risk, can constrain strategic choices, and may force more dilutive raises or unfavorable partnership terms if development needs accelerate.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $76.35M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.008.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 42,654,037 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (238.03% Upside)
$7.20 (238.03% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.94%
12-Months-Change
Fundamentals
Return on Equity
-201.43%
Trailing 12-Months
Asset Growth
61.20%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(238.03% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.00%
Insiders
1.76% Mutual Funds
4.13% Other Institutional Investors
89.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---